Hengrui Pharma’s BD Head Dr. Chen Dong Departs for AbbVie’s External Innovation Role
Dr. Chen Dong, Vice President and China Head of BD at Jiangsu Hengrui Pharmaceuticals Co.,...
Johnson & Johnson
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments...
Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...
EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook
US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...
Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder
US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal...
Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of...
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...
Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast...
Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...
MabPharm’s CMAB807 Biosimilar Receives Market Approval in Indonesia and Peru
Taizhou-based MabPharm Ltd (HKG: 2181), a specialist in monoclonal antibody (mAb) biosimilars, has announced the...
Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment
Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...